Lymphoma News

Older cancer survivors exhibited increased risk for cardiovascular disease than cancer-free individuals of the same age, according to a secondary analysis of a randomized study.

A real-world evaluation of axicabtagene ciloleucel for individuals with relapsed or refractory large B-cell lymphoma showed 5-year OS, PFS and disease-specific survival rates comparable to those observed in clinical trials.

Patients who received chimeric antigen receptor T-cell therapy did not exhibit increased risk for second primary malignancies compared with those who received other standard treatments, according to a systematic review and meta-analysis.

Many patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma do not undergo immunoglobulin G testing despite its potential to reduce likelihood of severe infections.

A telephone-administered, positive psychology intervention improved the well-being of patients who underwent hematopoietic stem cell transplantation, according to findings published in Journal of the National Comprehensive Cancer Network.

Deleting the CD5 gene from chimeric antigen receptor T cells improved their expansion, durability and tumor-killing capabilities, according to study findings.

The addition of tafasitamab-cxix to lenalidomide and rituximab improved outcomes for patients with relapsed or refractory follicular lymphoma, according to the agent’s manufacturer.

Spouses of people with cancer exhibited significantly higher risk for attempted suicide and suicide death than those whose spouses had not been diagnosed with cancer, according to a nationwide cohort study in Denmark.

The FDA approved the novel immunotherapy denileukin diftitox-cxdl for treatment of certain patients with relapsed or refractory cutaneous T-cell lymphoma.

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended the launch of proposed biosimilar rituximab candidate Ituxredi, Dr. Reddy’s Laboratories announced in a press release.